These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 26805787)

  • 21. Expanding the Application and Formulation Space of Amorphous Solid Dispersions with KinetiSol®: a Review.
    Ellenberger DJ; Miller DA; Williams RO
    AAPS PharmSciTech; 2018 Jul; 19(5):1933-1956. PubMed ID: 29846889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques.
    Meng F; Gala U; Chauhan H
    Drug Dev Ind Pharm; 2015; 41(9):1401-15. PubMed ID: 25853292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Solid State NMR Investigation for Molecular States of Specialized Formulation to Improve the Water Solubility of Poorly Water-soluble Drugs].
    Higashi K
    Yakugaku Zasshi; 2021; 141(9):1063-1069. PubMed ID: 34471007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.
    Löbmann K; Laitinen R; Strachan C; Rades T; Grohganz H
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):882-8. PubMed ID: 23567485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations.
    Srinarong P; de Waard H; Frijlink HW; Hinrichs WL
    Expert Opin Drug Deliv; 2011 Sep; 8(9):1121-40. PubMed ID: 21722000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of the carrier in the formulation of pharmaceutical solid dispersions. Part II: amorphous carriers.
    Van Duong T; Van den Mooter G
    Expert Opin Drug Deliv; 2016 Dec; 13(12):1681-1694. PubMed ID: 27267583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomimetic Dissolution: A Tool to Predict Amorphous Solid Dispersion Performance.
    Puppolo MM; Hughey JR; Dillon T; Storey D; Jansen-Varnum S
    AAPS PharmSciTech; 2017 Nov; 18(8):2841-2853. PubMed ID: 28560506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physical stabilization of low-molecular-weight amorphous drugs in the solid state: a material science approach.
    Qi S; McAuley WJ; Yang Z; Tipduangta P
    Ther Deliv; 2014 Jul; 5(7):817-41. PubMed ID: 25287388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ternary Solid Dispersions: A Review of the Preparation, Characterization, Mechanism of Drug Release, and Physical Stability.
    Budiman A; Lailasari E; Nurani NV; Yunita EN; Anastasya G; Aulia RN; Lestari IN; Subra L; Aulifa DL
    Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation, characterization and in vitro/vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability.
    Shuai S; Yue S; Huang Q; Wang W; Yang J; Lan K; Ye L
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):413-22. PubMed ID: 25669445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
    Caron V; Tajber L; Corrigan OI; Healy AM
    Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems.
    Wu W; Löbmann K; Rades T; Grohganz H
    Int J Pharm; 2018 Jan; 535(1-2):86-94. PubMed ID: 29102703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
    Qian F; Huang J; Hussain MA
    J Pharm Sci; 2010 Jul; 99(7):2941-7. PubMed ID: 20127825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-Amorphous Drug Formulations in Numbers: Recent Advances in Co-Amorphous Drug Formulations with Focus on Co-Formability, Molar Ratio, Preparation Methods, Physical Stability, In Vitro and In Vivo Performance, and New Formulation Strategies.
    Liu J; Grohganz H; Löbmann K; Rades T; Hempel NJ
    Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33804159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): Evaluating amorphous state and in vivo performance.
    Fule R; Dhamecha D; Maniruzzaman M; Khale A; Amin P
    Int J Pharm; 2015 Dec; 496(1):137-56. PubMed ID: 26471056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Solid dispersions: a strategy for poorly aqueous soluble drugs and technology updates.
    Alam MA; Ali R; Al-Jenoobi FI; Al-Mohizea AM
    Expert Opin Drug Deliv; 2012 Nov; 9(11):1419-40. PubMed ID: 23043303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Facile formation of co-amorphous atenolol and hydrochlorothiazide mixtures via cryogenic-milling: Enhanced physical stability, dissolution and pharmacokinetic profile.
    Moinuddin SM; Ruan S; Huang Y; Gao Q; Shi Q; Cai B; Cai T
    Int J Pharm; 2017 Oct; 532(1):393-400. PubMed ID: 28893583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Considerations for the selection of co-formers in the preparation of co-amorphous formulations.
    Yarlagadda DL; Sai Krishna Anand V; Nair AR; Navya Sree KS; Dengale SJ; Bhat K
    Int J Pharm; 2021 Jun; 602():120649. PubMed ID: 33915186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Felodipine-indomethacin" co-amorphous supersaturating drug delivery systems: "Spring-parachute" process, stability, in vivo bioavailability, and underlying molecular mechanisms.
    Li YW; Zhang HM; Cui BJ; Hao CY; Zhu HY; Guan J; Wang D; Jin Y; Feng B; Cai JH; Qi XR; Shi NQ
    Eur J Pharm Biopharm; 2021 Sep; 166():111-125. PubMed ID: 34119671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of Drug Crystallization and Molecular Interactions by Additives in Solid Dispersions for Improving Drug Bioavailability.
    Tran PHL; Duan W; Lee BJ; Tran TTD
    Curr Pharm Des; 2019; 25(18):2099-2107. PubMed ID: 31244413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.